Nipradilol is an alpha(1), beta-blocker with milder side effects than other beta-blockers used in humans. In this study the effects of nipradilol were compared with those of timolol maleate in dogs. Twelve clinically normal dogs (nine mongrels, two beagles, and one Akita) were used. We applied 0.25% nipradilol or 0.5% timolol maleate drops for a period of 28 days. Intraocular pressure (IOP) was measured before and after administration on the 2nd, 4th, 7th, 14th, 21st and 28th day. Blood pressure, pulse rate and coefficient of aqueous outflow (C-value) were also measured before and after administration on the 7th, 14th, 21st and 28th day. Both nipradilol and timolol maleate significantly lowered IOP from the 2nd day to the end of the study period. Nipradilol lowered IOP to an equivalent degree to timolol maleate. There was no significant change in blood pressure and pulse rate throughout the study period with administration of nipradilol. C-value showed a significant rise from the 14th day with administration of nipradilol, while it did not show any significant change during the study period with administration of timolol maleate. The reduction of IOP by nipradilol was similar to that by an existing beta-adrenergic antagonist, timolol maleate, but nipradilol was associated with fewer systemic side effects in dogs. Nipradilol appears to be a useful drug for treatment of glaucoma in dogs.

Administration, Topical↗

PubMedDate not supplied

[Severe and fatal non-A non-B hepatitis in 4 young and children].

Four cases on non-A, non-B acute hepatitis have been observed in infants of the same family. No evidence of hepatitis A or B (HBs-Ag, anti-HBs antibodies, HBe-Ag, anti-HBe and anti-HBc antibodies) could be detected in sera. Virological investigations showed no evidence of cytomegalovirus, Epstein-Barr virus, infection, etc. The two younger infants developed disseminated intravascular coagulation and died. The other two recovered without sequelae.

Antibodies, Viral↗